Altre lingue Sinovac Biotech Ltd.

Azioni

SVA

AGP8696W1045

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 22/02/2019			Variaz. 5gg	Var. 1 gen.
6,47 ^USD	-0,31%		-.--%	-.--%

18/01	Alternative Liquidity Index LP, un fondo gestito da Alternative Liquidity Capital, ha annullato l'acquisizione della partecipazione del 10,04% in Sinovac Biotech Ltd.	CI
2023	Gli scienziati vedono il rischio di un'opportunità persa per la ricerca sulla COVID lunga in Cina	RE

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Sinovac - WHO releases 2024-2025 Northern Hemisphere influenza vaccine component recommendations, changes to H3N2 virus	26/02
Sinovac Amends Shareholder Rights Plan	21/02
Beijing Sinovac Zhongwei Biotechnology Co., Ltd.'s 2024 information disclosure on environmental pollution prevention and control by hazardous wastes	26/01
Le conseil d'administration de Sinovac rejette à l'unanimité une offre partielle non sollicitée	18/01
Das Board of Directors von Sinovac lehnt einstimmig ein unaufgefordert abgegebenes Teilkaufangebot ab	18/01
El Consejo de Administración de Sinovac rechaza por unanimidad una OPA parcial no solicitada	18/01
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer	18/01
Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital cancelled the acquisition of 10.04% stake in Sinovac Biotech Ltd.	18/01
Alternative Liquidity Capital Announces Offer to Purchase Common Shares in Sinovac Biotech Ltd.	11/01
Scientists see risk of lost opportunity for long COVID research in China	14/12
Sinovac - Study shows, Children aged 3-8 years old receive 2 doses of influenza vaccine for better protection	30/10/23
Sinovac Biotech Ltd - A delegation from the Indonesian Ministry of Health visited Sinovac	26/10/23
Sinovac - Sharing and co-building China Sinovac has supplied more than 1.2 billion doses of vaccines to 62 'Belt and Road' countries	23/10/23
SINOVAC rend compte des progrès réalisés dans le cadre de son essai clinique concernant l’injection anti-COVID-19 à base d’anticorps SA55	11/09/23
SINOVAC informiert über die Fortschritte bei der klinischen Studie für den Anti-COVID-19-Antikörper SA55 Injection	11/09/23
SINOVAC informa sobre el desarrollo del ensayo clínico de su Inyección SA55 de anticuerpos anti-COVID-19	11/09/23
Sinovac Biotech : Clinical trials will advance treatment of COVID-19 infection - Form 6-K	11/09/23
SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection	11/09/23
Sinovac Biotech Ltd. Reports on the Clinical Trial Progress of Its Anti-Covid-19 Antibody Sa55 Injection	11/09/23
The first study on the protective effect of influenza vaccine for Chinese military personnel shows that Sinovac influenza vaccine has good immunogenicity and safety among military personnel	06/09/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Sinovac Biotech Ltd.

Azioni

SVA

AGP8696W1045

Altre lingue

Filtri